Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918526 | 0.87 | UCHL1 (0.36) | GAAKDM4EPOLBUCHL1ALDH1A1 | |
| SCHEMBL2849236 | 0.87 | TDP1 (0.42) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL31537484 | 0.85 | GAA (0.40) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL3336509 | 0.85 | GAA (0.50) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL17201292 | 0.84 | CA12 (0.41) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL23496925 | 0.83 | KDM4E (0.42) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL16113731 | 0.83 | UCHL1 (0.34) | GAAKDM4EUCHL1ALDH1A1MAPT | |
| SCHEMBL17239603 | 0.83 | MEN1 (0.38) | GAAKDM4EHTTUCHL1ALDH1A1 | |
| SCHEMBL29891154 | 0.82 | GAA (0.40) | GAAKDM4EHTTPOLBUCHL1 | |
| SCHEMBL3515967 | 0.82 | GAA (0.40) | GAAKDM4EHTTPOLBUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017165233-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-2831066-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2326633-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9096580-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-21 | — | — | US | disclosed |
| EP-2831066-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2015-02-04 | — | — | EP | disclosed |
| EP-2649067-B1 | BENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEPATITITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2588464-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| US-7994171-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2326633-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056510-A1 | Macrocyclic Compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119718-A1 | MACROCYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056510-A1 | Macrocyclic Compound | HSP90AB1, HSP90B1, HSP90AA1 | GAA 362/4885KDM4E 2183/4885HTT 891/4885 |
| US-20150141395-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | GAA 456/4885KDM4E 3000/4885HTT 4758/4885 |
| US-20100249094-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885KDM4E 4218/4885HTT 4681/4885 |
| US-20200291002-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | HAVCR2, UGT2B7, GOT1 | GAA 480/4885KDM4E 3114/4885HTT 4741/4885 |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GAA 162/4885KDM4E 4218/4885HTT 4681/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | GAA 480/4885KDM4E 3114/4885HTT 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.